KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Payables: 2010-2024

Historic Payables for Acadia Pharmaceuticals (ACAD) over the last 15 years, with Dec 2024 value amounting to $16.2 million.

  • Acadia Pharmaceuticals' Payables rose 13.97% to $21.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $76.1 million, marking a year-over-year increase of 0.39%. This contributed to the annual value of $16.2 million for FY2024, which is 7.70% down from last year.
  • Acadia Pharmaceuticals' Payables amounted to $16.2 million in FY2024, which was down 7.70% from $17.5 million recorded in FY2023.
  • Acadia Pharmaceuticals' 5-year Payables high stood at $17.5 million for FY2023, and its period low was $6.9 million during FY2021.
  • Its 3-year average for Payables is $15.5 million, with a median of $16.2 million in 2024.
  • Its Payables has fluctuated over the past 5 years, first declined by 19.04% in 2021, then surged by 85.37% in 2022.
  • Over the past 5 years, Acadia Pharmaceuticals' Payables (Yearly) stood at $8.5 million in 2020, then decreased by 19.04% to $6.9 million in 2021, then soared by 85.37% to $12.7 million in 2022, then spiked by 37.64% to $17.5 million in 2023, then fell by 7.70% to $16.2 million in 2024.